Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

HTTPS

Secure .gov websites use HTTPS
A lock (LockA locked padlock) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

 
NIH National Institute of Dental and Craniofacial Research (NIDCR) Home page
  • Health Info
  • Research
  • Grants & Funding
  • Careers & Training
  • News & Events
  • About Us
  • Health Info
    • Publications
    • Clinical Trials
    • Data & Statistics
    • Finding Dental Care
  • Research
    • Research Conducted at NIDCR (Intramural)
    • Research Funded by NIDCR (Extramural)
    • Human Subjects Research
    • Clinical Trials
    • Data & Statistics
    • Scientific Data Sharing
    • Research Priorities
    • Research Investments & Advances
    • Oral Health in America Report
    • COVID-19
  • Grants & Funding
    • Notices of Funding Opportunities
    • Grant Programs and Contacts
    • Funding Priorities
    • Funded Research
    • Human Subjects Research
    • Scientific Data Sharing
  • Careers & Training
    • Research Training at NIDCR (Intramural Opportunities)
    • Funding for Research Training (Extramural Opportunities)
    • Job Openings
    • Loan Repayment
    • Staff Contacts
  • News & Events
    • NIDCR News
    • Newsletter
    • Grantee News
    • Events
    • Images
    • For Reporters
  • About Us
    • Leadership & Staff
    • Advisory Committees
    • Strategic Plan
    • Oral Health in America Report
    • Congressional & Budget
    • Job Openings
    • Getting to NIDCR
    • Contact Us
    • Mission

Breadcrumb

  1. Home
  2. News & Events
  3. NIDCR News
  4. NIDCR News 2023
News & Events
  • NIDCR News
  • Newsletter
  • Grantee News
  • Events
  • Images
  • For Reporters
NIDCR EMAIL UPDATES 
Subscribe to receive NIDCR emails

Therapy for Rare Bone Disorder Shows Promise in NIH Clinical Trial

Medication is the first to reduce bone-weakening process in patients with fibrous dysplasia

April 4, 2023
By: Tiffany Chen
Bone scans of a patient before (left) and after (right) a six-month denosumab treatment show reduced turnover within fibrous dysplasia lesions (dark-colored patches).
Bone scans of a patient before (left) and after (right) a six-month denosumab treatment show reduced turnover within fibrous dysplasia lesions (dark-colored patches). | Alison Boyce, NIDCR

A clinical trial at the National Institutes of Health (NIH) found that a medication, denosumab, significantly reduced abnormal bone turnover in adults with fibrous dysplasia, a rare disease marked by weak and misshapen bones. Bone turnover, a process in which old bone is continuously replaced with new bone, is unusually accelerated in fibrous dysplasia and contributes to bone abnormalities. The study of eight participants was carried out by researchers from NIDCR and the NIH Clinical Center. The results, which showed that denosumab may improve patients’ quality of life by enabling healthy bone formation, were published as a correspondence report in the New England Journal of Medicine.

Fibrous dysplasia stems from gene mutations that cause scar-like (fibrous) tissue to replace healthy bone starting in early childhood. These fibrous lesions, which are marked by accelerated bone turnover, weaken bones, leading to bone deformities, fractures, physical disabilities, and pain. In some cases, the lesions can press up against organs and nerves, impairing functions like vision and breathing.

“Surgery is still the standard treatment for fractures and deformities caused by fibrous dysplasia,” said senior author Alison Boyce, M.D., a clinical investigator at NIDCR. “Denosumab is the first medication that appears to affect how fibrous dysplasia lesions behave and improves patients’ disease outcomes.”

Denosumab is a medication licensed by the U.S. Food and Drug Administration to treat bone problems from osteoporosis and cancer. It blocks a protein called RANKL (receptor activator of nuclear factor kappa-Β ligand), which is elevated in patients with fibrous dysplasia and is thought to boost bone turnover.

In the phase two clinical trial, eight women received high doses of denosumab over six months. At the end of the treatment period, patients’ bone biopsies and scans showed a marked reduction in bone turnover within lesions. Proteins in the blood associated with bone turnover also dropped to normal levels. These results indicated that the treatment improved the quality and strength of patients’ bones.

Patients also noted reduced complications while taking denosumab. One patient with lesions in the ribs reported increased lung function. Another participant with fibrous dysplasia in the skull experienced vision improvements.

“This trial is the culmination of 25 years of clinical research at NIDCR to understand the underlying mechanisms of fibrous dysplasia and to identify promising treatments,” said NIDCR Director Rena D’Souza, D.D.S., Ph.D.

While denosumab showed promise, abnormal bone turnover returned for all but one of the patients after they stopped taking the medication. In four patients, bone turnover exceeded pre-treatment levels. Dr. Boyce noted that it will be crucial for clinicians to factor in these risks when treating patients.

To determine whether earlier intervention with denosumab can prevent lesions from forming altogether, Dr. Boyce and her team are now testing the medication in a new clinical trial for children with fibrous dysplasia.

Related Links

  • Cracking Down on a Rare Bone Disorder
  • The Gut’s Role in Oral Bone Health
  • Tooth Protein Prevents Bone Loss in Mice

Reference

de Castro LF, Michel Z, Pan K, Taylor J, Szymczuk V, Paravastu S, et al. Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone. N Engl J Med. 2023 Feb 23;388(8):766-768. DOI: 10.1056/NEJMc2214862

NIH Support: In addition to NIDCR, support for this research came from the NIH Clinical Center.

Attention Editors

Reprint this article in your own publication or post to your website. NIDCR News articles are not copyrighted. Please acknowledge NIH's National Institute of Dental and Craniofacial Research as the source.

Subscribe for NIDCR Updates

Receive email updates about the latest advances in dental, oral, and craniofacial research.

Subscribe

Last Reviewed
October 2024

Previous Years' News

2024 | 2023 | 2022 | 2021

 

NIH
  • Home
  • Web Policies
  • Privacy
  • Contact Us
  • Freedom of Information Act
  • No Fear Act
  • Office of Inspector General
  • HHS Vulnerability Disclosure
  • Employee Intranet - Staff Only
Back to top